Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026)

Alnylam Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $4.1 billion for Q1 2026.

• Quarterly Total Liabilities fell 1.08% year-over-year to $4.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 billion (down 1.08% YoY) and the FY2025 annual result came in at $4.2 billion, changed 0.1% from the prior year.
• Total Liabilities was $4.1 billion for Q1 2026 at Alnylam Pharmaceuticals, down from $4.2 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $4.6 billion in Q3 2025 and bottomed at $3.0 billion in Q1 2022.
• A 5-year average of $3.9 billion and a median of $4.0 billion in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 32.63% — and 2026, when it slipped 1.08%.
• Alnylam Pharmaceuticals' Total Liabilities stood at $3.7 billion in 2022, then climbed by 9.34% to $4.1 billion in 2023, then advanced by 3.02% to $4.2 billion in 2024, then advanced by 0.1% to $4.2 billion in 2025, then fell by 2.94% to $4.1 billion in 2026.
• Business Quant data shows ALNY's Total Liabilities at $4.1 billion in Q1 2026, $4.2 billion in Q4 2025, and $4.6 billion in Q3 2025.